Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 29 of 29 publications.

Wolowacz SE, Roskell NS, Christie A, Kerr G, Cameron D. The cost of hospital care for relapsed breast cancer in the UK based on a large patient-level resource utilisation dataset. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy.

Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy.

Gregson N, Sparrowhawk K, Mladsi DM. Global pricing and reimbursement strategy: an integrated analytical framework. Presented at the 2005 ISPOR 8th Annual European Congress; November 8, 2005. Florence, Italy.

Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005 Nov 1;14(11):1133-50.

Wolowacz SE, Roskell NS, Christie A, Kerr G, Cameron D. Per-patient cost of hospital care for advanced breast cancer in the UK based on a large patient-level resource utilisation dataset. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A42.

Earnshaw SR, Javitt JC, Graham CN, Brogan AJ, Zlateva GP, Shah S, Adamis AP. Modeling treatments for subfoveal choroidal neovascularization secondary to age-related macular degeneration: cost-effectiveness methods. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A179.

Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6).

Pignone M, Earnshaw SR. Cost-effectiveness of aspirin for the primary prevention of cardiovascular events in women. Poster presented at the Society of Medical Decision Making; October 2005.

Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.

Ettinger B, Earnshaw SR, Graham CN, Amonkar MM, Baran RW. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with ibandronate. Poster presented at the American Society for Bone and Mineral Research (ASBMR) 27th Annual Meeting; September 2005.

Ball EV, Stenson PD, Abeysinghe SS, Krawczak M, Cooper DN, Chuzhanova NA. Microdeletions and microinsertions causing human genetic disease: common mechanisms of mutagenesis and the role of local DNA sequence complexity. Hum Mutat. 2005 Sep;26(3):205-13. doi: 10.1002/humu.20212

Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Economics of hepatitis A immunization. Presented at the U.S. Advisory Committee on Immunization Practices; June 2005. Atlanta, GA.

Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Update: economics of hepatitis A virus immunization. Presented at the ACIP Hepatitis Working Group; June 2005.

Rein DB, Hicks KA, Wirth KE, Hoerger TJ. Results of RTI's cost-effectiveness evaluation of childhood hepatitis A vaccination strategies. Presented at the U.S. Advisory Committee on Immunization Practices (ACIP); June 2005. Atlanta, GA.

Davis KL, Candrilli SD, Kan H, Lucero MA, Covington M. Estimating the effects of diabetic peripheral neuropathy and diabetic retinopathy on quality-of-life using data from the 2001-2002 national health and nutrition examination survey. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 18, 2005. [abstract] Value Health. 2005 May; 8(3):365.

Davis KL, Candrilli SD, Kan HJ, Lucero MA, Covington MT. Estimating the effect of symptoms of diabetic peripheral neuropathy and diabetic retinopathy on quality-of-life using data from the 2001-2002 national health and nutrition examination survey. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 2005. Washington, DC. [abstract] Value Health. 2005 May; 8(3):365.

Candrilli SD, Davis KL, Kan H, Lucero MA, Covington M. Burden of illness associated with symptoms of diabetic peripheral neuropathy and diabetic retinopathy. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 18, 2005. [abstract] Value Health. 2005 May; 8(3):357.

Ettinger B, Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R. Modeled cost impact of persistence with bisphosphonate therapy for women with postmenopausal osteoporosis. Poster presented at the Academy of Managed Care Pharmacy 17th Annual Meeting & Showcase; April 23, 2005.

Earnshaw SR, Pankaj PA, Candrilli SD, DePlatchett J, Graham CN, Williams L. Impact of pediatric asthma treatment on managed care organization budget. Poster presented at the 2005 AMCP 17th Annual Meeting & Showcase; April 1, 2005.

Earnshaw SR, Patel P, Candrilli SD, Graham CN, Deplatchett J. Impact of treatment on exacerbations in pediatric asthma in managed care organizations. Poster presented at the 2005 AMCP 17th Annual Meeting & Showcase; April 2005.

Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R, Hebborn A. The impact of persistency on economic models for bisphosphonate therapy in osteoporosis. Poster presented at the 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; March 26, 2005. Rome, Italy.

Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):65-79.

Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.

Bray JW, Davis KL, Graver L, Schroeder D, Buck JA, Dilonardo J, Vandivort R. Mental health and substance abuse treatment utilization among individuals served by multiple public agencies in 3 states. J Behav Health Serv Res. 2005 Jan 1;32(3):282-93.

Strickland A, Brogan AJ, Krauss J, Martindale R, Cresci G. Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation. J Parenter Enter Nutr. 2005 Jan 1;29(1 Suppl):S81-91.

Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005 Jan 1;142(5):323-32.

Brogan AJ, Stidham S. A note on separation in mean-lower-partial-moment portfolio optimization with fixed and moving targets. IIE Trans. 2005 Jan 1;37(10):901-6.

Gaffney L, Sherrill B, Wolowacz SE, Allen R, Connolly M, Kirsch J. Evaluating the predictors of health-related quality of life in European respondents with restless legs syndrome. Poster presented at the ICPD meeting; 2005; 2005. Berlin, Germany.

Van Houtven CH, Wilson MR, Clipp EC. Informal care intensity and caregiver drug utilization. Rev Econ Househ. 2005;3(4):415-33.